10 results about "Induced pluripotent stem cell" patented technology

The present invention relates to NK cells with an improved ability to target and kill cancer cells and use thereof. Specifically, the present invention relates to: iPSC-based NK cells into which a chimeric antigen receptor targeting a specific cancer antigen, CXCR4 and CCR7 genes, which are chemokine receptors, and an IL-15 / IL-15Rα (IL-15RF) gene are introduced; and use thereof for treating cancer. The iPSC-based NK cells according to the present invention can not only directly target a specific cancer antigen by the introduced CAR, but can also activate NK cells and enhance the proliferation thereof by regulating intracellular signaling and tumor microenvironment by the introduced CXCR4 and CCR7 and the introduced IL-15RF. Therefore, the NK cells into which multiple genes are introduced, according to the present invention, can efficiently target and attack cancer cells, and thus can be effectively used for the treatment of cancer diseases.

The present application provides a method for producing, from pluripotent stem cells, neural progenitor cells of the midbrain floor plate region or dopaminergic neural progenitor cells, the method comprising (1) inducing differentiation of pluripotent stem cells into neural progenitor cells of the midbrain floor plate region, and optionally (2) inducing differentiation of the neural progenitor cells of the midbrain floor plate region, which are obtained by the differentiation induced in (1), into dopaminergic neural progenitor cells, wherein all or part of the differentiation induced in (1) includes culturing the cells in a medium containing an agonist for LPA receptor.

In particular, compositions comprising iPSC-derived parietal cell precursors (iMPCs) generated using NK3 homeobox 1 (NKX3.1; parietal cell fate-determining transcription factor) and methods for their preparation and use are described herein. In addition, in particular, methods for maturing iMPCs into functional parietal cell subtypes, including smooth muscle cells, perivascular cells, and fibroblasts, as well as methods for increasing angiogenesis, angiogenesis, and cell junctions, are described herein. iMPCs mediate the formation of functional blood vessels when transplanted together with endothelial cells (ECs); thus, methods for modeling vascular diseases (e.g., 3D vascular organoids (VOs)) and therapeutic vascularization, comprising a method of administering iMPCs and ECs and a step of administering iMPCs and ECs, are also described herein.

This invention provides a gene therapy for Deutsche Syndrome (DSS) and relates to the field of clinical medical technology. It provides highly efficient pegRNA / ngRNA sequences and their application methods, validating the effectiveness of the lead editing system in treating SDS in two in vitro models: induced pluripotent stem cells (iPSCs) and hematopoietic stem / progenitor cells (HSPCs). Furthermore, the therapeutic effect of lead editing on SDS was identified in vivo by transplanting edited HSPCs, laying the foundation for clinical translation.

To provide a novel method for producing iPS cells that requires less patient-derived somatic cells as raw material and reduces the use of reagents (e.g., viral vectors) compared to conventional methods. [Solution] The present invention provides a method for producing iPS cells using a cell processing device. The cell processing device has a closed system portion in which a sealed container for supplying materials and a centrifugal chamber configured to perform counterflow centrifugal separation are connected via a connecting conduit. The production method involves performing a step (s1) of contacting somatic cells with reprogramming factors while performing counterflow centrifugal separation in the centrifugal chamber, while maintaining the closed nature of the closed system portion.

Described herein are methods and culture medium, useful for inducing polarization in multipotent stem cells. Additionally, described herein are multipotent cells produced by the methods and culture medium of this disclosure that are useful therapeutic agents. Also described herein are extracellular vesicles and factors secreted by multipotent cells that are produced by the methods and culture medium of this disclosure that are useful as therapeutic agents.

This invention relates to the field of hematopoietic stem cell technology, specifically to a culture medium combination and method for inducing pluripotent stem cells to differentiate into hematopoietic stem cells. Addressing the problems of low efficiency and low yield associated with existing methods that require digestion and sorting for pluripotent stem cell differentiation into hematopoietic stem cells, resulting in only one harvest after induction, this invention provides a culture medium combination and method that enables "one-time induction, multiple harvests." This invention adds CHIR99021 to culture medium I and SB431542 to culture medium III, combined with other culture medium components and dynamic culture, to achieve highly efficient mesoderm induction. Combined with periodic replacement of culture medium V, digestion and sorting are unnecessary, allowing for more than three periodic harvests of high-purity (CD34) stem cells in the same container from a single induction. + CD45 + >95% hematopoietic stem cells. This invention simplifies the operation steps, eliminating the need for re-seeding, digestion, or sorting and enrichment, significantly increasing the yield per batch and making it suitable for industrial production; the entire process is free of foreign substances, meets GMP standards, and the resulting cells meet clinical application requirements.

Human skeletal muscle stem cells were generated from facioscapulohumeral muscular dystrophy (FSHD) and healthy control iPSC using a transgene-free skeletal muscle differentiation protocol and production of stable iMyoblasts. Analyses revealed that FSHD and healthy control iMyoblasts are embryonic-like myogenic cells that undergo myotube differentiation ex vivo by growth factor depletion and are efficiently transplantable into the tibialis anterior (TA) muscles of NSG mice, where human muscle under-goes embryonic-to-adult myosin isoform switching. The DUX4 FSHD disease gene maintains its hypomethylated disease state inFSHD iPSC and iMyoblast, and its expression is upregulated during myotube differentiation and in muscle xenografts. Consequently, these iMyoblasts accurately exhibit the molecular pathology of human muscular dystrophies and are useful for the development of drug, gene editing and stem cell therapeutics.

This disclosure relates to the use of dielectric spectroscopy for selecting cells, typically cells engineered by recombinant methods, but also to hybridoma cell lines that produce antibodies and express peptides such as antibodies; CAR-T cells; induced pluripotent stem (IPS) cells; and cells derived from IPS cells.

Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and / or in / dels in one or more selected endogenous genes.